Analysts: Wal-Mart in for Sales Recovery and 3 More Research Notes to Check Out

Wal-Mart (NYSE:WMT): Susquehanna has previewed Wal-Mart’s second-quarter earnings report, and it believes that the company remains well positioned to capitalize on the value-seeking mid- to low-end consumer while showing a modest improvement in same-store sales, though the firm has immediate concerns over the back-to-school season and recent trends in the low-consumer market. The shares remain Positive rated with an $85 price target.


Cubist (NASDAQ:CBST): Cowen has discussed the positive expectations for Cubist’s Phase lll data for its gram-negative drug, and noted its market is significantly under-penetrated. The firm believes Cubist remains undervalued and on a standalone basis would be worth $75-$80 per share, but worth more than $95 per share to a strategic buyer. The shares are Outperform rated.


Humana (NYSE:HUM): Cantor has raised its price target for Humana to $105 from $90, citing the company’s better-than-expected second-quarter results and a better outlook for Medicare Advantage in 2014. The firm keeps a Buy rating on the stock.


USA Compression (NYSE:USAC): Wells Fargo has upgraded USA Compression to Outperform from Market Perform, citing enhanced growth and a reduced risk profile following the acquisition of compression assets. The firm raised its price target range for shares to $27-$29 from $20-$22.


Don’t Miss: Cooling Consumer Spending Leaves Macy’s with Chilly Q2 Sales.